Florbetapir scans help with patient diagnosis and management
23 July 2015 | By Victoria White
New data shows that knowledge of amyloid status as determined by Florbetapir F 18 Injection imaging altered diagnosis and management of patients...
List view / Grid view
News
Depomed receives unsolicited proposal from Horizon Pharma
23 July 2015 | By Victoria White
Depomed has confirmed that it has received an unsolicited proposal from Horizon Pharma to acquire all of the outstanding shares of Depomed...
J&J and Norvatis to fight it out in the axSpA treatment space
22 July 2015 | By Victoria White
Stelara has progressed into Phase III development for axSpA and, following its anticipated approval, is forecast to achieve sales of $244.7 million in 2024...
Comark Instruments prevents high-volume, high-value inventory spoilage and significant revenue loss for VH Bio
22 July 2015 | By Comark Instruments
VH Bio is a leading supplier and distributer for the Life Sciences industry within the United Kingdom and Republic of Ireland...
Promising Phase 3 results for E/C/F/TAF regimen presented at IAS
22 July 2015 | By Victoria White
Detailed 48-week data from a Phase 3 study evaluating E/C/F/TAF regimen in patients with HIV-1 was presented at the 8th IAS Conference...
Aducanumab demonstrates promising Phase 1b results in Alzheimer’s disease
22 July 2015 | By Victoria White
Biogen has announced new results from an interim analysis of the Phase 1b PRIME study of aducanumab in patients with prodromal or mild Alzheimer’s disease...
Data suggests Lilly’s solanezumab slows progression of mild Alzheimer’s
22 July 2015 | By Victoria White
Lilly has announced results suggesting that solanezumab slows the progression of Alzheimer's in patients with mild disease...
Novavax announces positive top-line data from Phase 1 Ebola vaccine trial
22 July 2015 | By Victoria White
Novavax has announced positive top-line data from a Phase 1 clinical trial of its Ebola virus glycoprotein recombinant nanoparticle vaccine candidate...
Phase III study of selumetinib in uveal melanoma fails to meet primary endpoint
22 July 2015 | By Victoria White
A Phase III study of selumetinib in combination with dacarbazine for the treatment of metastatic uveal melanoma failed to meet its primary endpoint...
HIV-1 maturation inhibitor BMS-955176 demonstrates positive new Phase IIa results
22 July 2015 | By Victoria White
Bristol-Myers Squibb has announced additional Phase IIa data for BMS-955176, a novel investigational agent designed to prevent the maturation of HIV-1...
NICE gives green light to two eye treatments for treating diabetic macular oedema
22 July 2015 | By Victoria White
NICE has recommended aflibercept solution for injection and dexamethasone implant as treatment options for some people with diabetic macular oedema...
NICE recommends Tegaderm CHG dressing to reduce catheter infections
22 July 2015 | By Victoria White
NICE has recommended the use of 3M Tegaderm CHG IV securement dressing to hold catheters in place securely, reducing the risk of catheter related infections...
BioMarin provides programme update for talazoparib in metastatic breast cancer
21 July 2015 | By Victoria White
BioMarin has provided an update on the ABRAZO Phase 2 study of its poly ADP-ribose polymerase (PARP) inhibitor, talazoparib...
FDA grants Breakthrough Therapy Designation to Bristol-Myers Squibb’s BMS-663068
21 July 2015 | By Victoria White
The FDA has granted Breakthrough Therapy Designation to BMS-663068 for the treatment of HIV-1 infection in heavily treatment-experienced adult patients...
Tekmira to change company name; suspends development of ebola drug
21 July 2015 | By Victoria White
Tekmira Pharmaceuticals Corporation has announced plans to change its corporate name to Arbutus Biopharma Corporation, to be effective by 3 August 2015...
